Compare Phillips 66 (PSX) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Relay Therapeutics Inc. Common Stock — how do they compare? Phillips 66 trades at $278.55 (market cap $112.36B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.82B). The key difference: Phillips 66 is far larger — about 29.4× Relay Therapeutics Inc. Common Stock's market cap, and Phillips 66 pays a 1.8% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| PSX | RLAY | |
|---|---|---|
Market Cap | $112.36B | $3.82B |
Volume | 2,374,751 | 4,332,079 |
Sector | Energy | Health |
52-Week High | $281.60 | $20.75 |
52-Week Low | $126.76 | $6.03 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $128.83B | $2.93B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $271.62, up 0.68% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $279. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue declined to $132.38B in 2025, but net income improved to $4.40B, and 2026 projections show a rebound to $152.2B revenue and $7.1B net income. The company maintains a solid balance sheet with $72.58B in total assets and recently announced a $1.27 dividend for H2-2026.
The outlook for PSX is positive, supported by structural refining margins and AI-driven operational efficiencies. Investment opportunities include potential price appreciation toward the $279 consensus target and a sustainable dividend. Risks include exposure to volatile oil prices, regulatory changes such as potential diesel export bans, and execution challenges in maintaining profitability amid shifting energy demand.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
